Drugs / Cavrotolimod
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03086278 | Oct 2017 → Aug 2018 | — | Exicure, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03684785 | Dec 2018 → Mar 2022 | cutaneous neuroendocrine carcinoma, head and neck squamous cell carcinoma, melanoma, skin squamous cell carcinoma | Exicure, Inc. | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cavrotolimod | “Here we designed and characterized cavrotolimod (formerly AST-008), an immunostimulatory spherical nucleic acid (SNA) compound targeting Toll-like receptor 9 (TLR9).” PMID 36582243 ↗ Dec 2022 |
| Known as | AST-008 | “Here we designed and characterized cavrotolimod (formerly AST-008), an immunostimulatory spherical nucleic acid (SNA) compound targeting Toll-like receptor 9 (TLR9).” PMID 36582243 ↗ Dec 2022 |
| Known as | AST-008 OLIGONUCLEOTIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650386 ↗ |
| Action | Activate | “AST-008 is a toll-like receptor 9 agonist.” NCT03086278 ↗ |
| Modality | Oligonucleotide (other) | “an immunostimulatory spherical nucleic acid (SNA) compound” PMID 36582243 ↗ Dec 2022 |
| Route | Subcutaneous | “all received a single subcutaneous dose of cavrotolimod.” PMID 36582243 ↗ Dec 2022 |
| Target | TLR9 | “a novel spherical nucleic acid configuration of a toll-like receptor 9 agonist oligonucleotide” PMID 40713179 ↗ Jul 2025 |